Key Takeaways
- On September 9, 2026, ARK Invest liquidated 84,392 Alphabet shares valued at $28.6 million
- The investment firm acquired 43,091 Meta Platforms shares totaling $26.4 million following the Muse AI agent debut
- Meta’s stock surged 6.55% while Alphabet declined 2.28% during the trading session
- ARK expanded positions in Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics
- The firm reduced its Tempus AI holdings by approximately $1.5 million
On Wednesday, September 9, 2026, Cathie Wood’s ARK Invest executed a series of significant portfolio adjustments. The investment firm divested 84,392 Alphabet shares across its ARKK and ARKW exchange-traded funds, representing approximately $28.6 million in value.
Simultaneously, ARK accumulated 43,091 Meta Platforms shares worth approximately $26.4 million. The social media giant’s stock experienced a 6.55% increase following the company’s introduction of Muse, an artificial intelligence agent designed to manage tasks including e-commerce transactions, travel arrangements, and email correspondence.
Mark Zuckerberg, Meta’s chief executive, characterized the offering as a component of the company’s progression toward achieving “personal superintelligence.” The product release provided market participants with tangible evidence of Meta’s strategy for deploying its substantial AI investments.
The social media company anticipates capital expenditures ranging from $130 billion to $145 billion throughout the year, with AI development accounting for a significant proportion of this outlay.
Alphabet experienced a 2.28% stock decline on the identical trading day. Mizuho’s Lloyd Walmsley suggested that Meta’s Muse introduction might reignite investor apprehensions regarding Google’s Gemini AI platform and the potential impact of AI-powered agents on conventional search business models.
ARK’s divestment of Alphabet holdings represents a continuation of a multi-week trend rather than an isolated transaction. Wednesday’s sale extended the firm’s ongoing reduction strategy.
Biotech Sector Acquisitions by ARK
During the same trading session, ARK expanded multiple biotechnology investments. The firm acquired 271,159 Beam Therapeutics shares valued at approximately $7.3 million. Beam’s stock decreased 6.17% to $25.18 following the company’s release of refreshed Phase 1/2 clinical trial data for BEAM-302, a therapeutic candidate targeting alpha-1 antitrypsin deficiency.
ARK purchased 47,113 CRISPR Therapeutics shares for roughly $2.6 million. CRISPR’s stock price declined 2.43% to $53.45 throughout the session.
Additionally, the investment firm obtained 204,206 Intellia Therapeutics shares totaling approximately $2.6 million. Intellia experienced a 4.16% stock decrease to $12.21.
The Food and Drug Administration recently granted Priority Review status to Intellia’s lonvo-z application. Regulatory authorities are scheduled to issue their determination by March 10, 2027. Upon approval, lonvo-z would represent the inaugural single-administration therapy for hereditary angioedema utilizing in vivo CRISPR-based genetic modification.
Regarding divestments, ARK decreased its Tempus AI allocation by 22,767 shares, representing roughly $1.5 million. Tempus stock fell 4.68% during the trading period. ARK has systematically reduced its Tempus position across multiple recent sessions.
ARK’s September 9 transactions illustrate a strategic reallocation from Alphabet toward Meta Platforms and biotechnology securities, capitalizing on valuation decreases while reducing exposure to underperforming positions.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
